ERAS — Erasca, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1761918 ·
Last close
$13.89
Market Cap
$4.87B
52W High
$24.28
52W Low
$2.71
ADV30
5,532,589
Next earnings
2026-11-12
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -59,521,000 -51,331,000 998,936,000 118,959,000 82,198,000
Jun 2026 0 — -47,619,000 -44,079,000 435,054,000 42,542,000 73,185,000
Mar 2026 0 — -37,911,000 -183,440,000 461,234,000 47,256,000 67,706,000
Dec 2025 0 — -32,604,000 -29,092,000 396,154,000 73,805,000 70,983,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-98,022,000
Investing CF
$-173,923,000
Financing CF
$248,344,000
CapEx
$-154,059,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.95
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,119,728,000
Inventory
—
Receivables
—
ST Investments
$226,196,000
EBIT TTM
$-150,680,000
Pretax Income TTM
$-287,223,000
Interest Exp TTM
—
Analysts
9

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -131,405,000 -124,546,000 396,154,000 70,983,000 325,171,000 -95,455,000
Dec 2024 0 -157,087,000 -161,650,000 502,526,000 79,027,000 423,499,000 -109,417,000
Dec 2023 0 -141,525,000 -125,042,000 395,297,000 78,611,000 316,686,000 -101,217,000
Dec 2022 0 -145,450,000 -242,805,000 514,909,000 103,056,000 411,853,000 -103,264,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-287,223,000
OpCashFlow TTM
—
Assets (Latest)
$435,054,000
Forward EPS
$-0.75

Max Pain — expiry 2026-12-18

max pain strike: $12.50 · spot: $13.76 · call oi: 11,669 · put oi: 3,892
Expected Move to 2026-12-18: ±$5.00 (36.34%) — implied range $8.76 – $18.76 · ATM straddle on $14.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
DNTH Dianthus Therapeutics, Inc. /DE/ $4.90B $86.98 —
COGT Cogent Biosciences, Inc. $4.85B $27.85 —
TVTX Travere Therapeutics, Inc. $4.91B $51.10 —
PTCT PTC THERAPEUTICS, INC. $5.04B $60.36 —
GIKLY Grifols SA $4.69B $5.55 —

News headlines (Yahoo Finance, 1h cache)

Erasca Partners With Bristol Myers Squibb to Evaluate ERAS-0015 Combination Treatment for Pancreatic Cancer
2026-11-18 11:43 · Yahoo
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
2026-11-17 23:40 · Yahoo
Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
2026-11-16 13:01 · Yahoo
Erasca Reports Third Quarter 2026 Business Updates and Financial Results
2026-11-12 21:01 · Yahoo
Erasca Stock In Focus As Combination Trial Begins
2026-11-12 03:13 · Yahoo
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
2026-11-04 13:30 · Yahoo
Erasca to Present at Upcoming Conferences in November
2026-11-03 13:00 · Yahoo
Erasca (ERAS), What Is Driving Attention Around The Stock Today?
2026-10-27 18:15 · Yahoo
Erasca (ERAS) Stock Looks Above Fair Value After Its 5x Run
2026-10-19 06:08 · Yahoo
Sector Update: Healthcare Stocks Mixed Friday Afternoon
2026-10-16 17:44 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.